 |
|
|
|
 |
|
|
| Article 1 to 10 out of 79 concerning GlaxoSmithKline plc (GSK)
|
-
GSK commences succession plan for management of vaccines business
(16 Mar 2010)
GlaxoSmithKline (GSK) announced management changes related to its Vaccines business as part of a planned succession strategy. With immediate effect Jean Stephenne is appointed Chairman, GSK Biologicals. Mr Stephenne will assume this role in addition ...
-
to-BBB and GSK to collaborate on brain delivery of a biologic product
(04 Mar 2010)
to-BBB announced that it has entered into a research collaboration with GlaxoSmithKline (GSK) involving to-BBB’s proprietary G-Technology® in delivering a biological compound to the brain.Under the terms of the collaboration, to-BBB will work with ...
-
GSK announces appointment of Philippe Fauchet as President of GSK Japan
(08 Feb 2010)
GSK announced the appointment of Philippe Fauchet as President of GSK Japan. Philippe will report to Marc Dunoyer, who takes the new role as Chairman of GSK Japan. Marc will continue to take overall leadership responsibility for GSK’s ...
-
Apeiron and GSK sign an exclusive license agreement for Apeiron's therapeutic enzyme project APN01
(05 Feb 2010)
Apeiron Biologics AG announced the signing of an agreement granting GlaxoSmithKline (GSK) exclusive rights to APN01 (recombinant human Angiotensin Converting Enzyme 2, rhACE2), an enzyme biotherapeutic currently in Phase 1 development for the ...
-
Arzerra (Ofatumumab) Receives Positive Opinion for Conditional Approval in Europe for Refractory Chronic Lymphocytic Leukaemia
(26 Jan 2010)
GlaxoSmithKline and Genmab A/S announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Arzerra(TM) (ofatumumab), for the treatment of refractory chronic lymphocytic ...
-
Largest academic-industry collaboration for drug discovery in depression and schizophrenia launched
(21 Jan 2010)
An international consortium of scientists, led by H. Lundbeck A/S and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for schizophrenia ...
-
ChemoCentryx receives an option payment of USD 35 million from GlaxoSmithKline for a licensing agreement
(18 Jan 2010)
GlaxoSmithKline (GSK) has exercised its option for a licensing agreement for ChemoCentryx’ leading drug candidate Traficet-EN. GSK gains the exclusive licence to develop and commercialise Traficet-EN, a drug for the treatment of chronic inflammatory ...
-
Galapagos and GlaxoSmithKline broaden arthritis alliance
(17 Dec 2009)
Expansion of programs based on promising drug target GT622 €6.5 M payment this year and additional milestones
Galapagos NV announced that it has expanded its arthritis alliance with GlaxoSmithKline to include additional drug discovery programs based on novel drug target GT622. Under the terms of this extension, Galapagos will receive a payment from GSK of ...
-
GSK study showed targeted therapy combination achieved 14 month overall survival in patients with advanced breast cancer
(14 Dec 2009)
In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study ...
-
Intercell and GSK form strategic alliance to develop and commercialize innovative needle-free patch-based vaccines
(11 Dec 2009)
Intercell and GlaxoSmithKline Biologicals SA (GSK) announced an agreement to form a strategic alliance to accelerate the development and commercialization of needle-free, patch-based vaccines. The agreement will include Intercell's candidate vaccine ...
Additional information
GlaxoSmithKline plc (GSK)
Brentford, Middlesex, United Kingdom
Company
|
|
|
|
|
|
Top
